- Home
- TURN vs INKT Comparison
TURN vs INKT Comparison
Compare TURN & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- INKT
- Stock Information
- Founded
- TURN 1981
- INKT 2017
- Country
- TURN United States
- INKT United States
- Employees
- TURN N/A
- INKT N/A
- Industry
- TURN Finance/Investors Services
- INKT Medicinal Chemicals and Botanical Products
- Sector
- TURN Finance
- INKT Health Care
- Exchange
- TURN Nasdaq
- INKT Nasdaq
- Market Cap
- TURN 49.6M
- INKT 69.2M
- IPO Year
- TURN N/A
- INKT 2021
- Fundamental
- Price
- TURN $4.96
- INKT $15.15
- Analyst Decision
- TURN
- INKT Buy
- Analyst Count
- TURN 0
- INKT 3
- Target Price
- TURN N/A
- INKT $37.50
- AVG Volume (30 Days)
- TURN 33.2K
- INKT 45.1K
- Earning Date
- TURN 02-26-2018
- INKT 11-13-2025
- Dividend Yield
- TURN N/A
- INKT N/A
- EPS Growth
- TURN N/A
- INKT N/A
- EPS
- TURN 0.29
- INKT N/A
- Revenue
- TURN $488,011.00
- INKT N/A
- Revenue This Year
- TURN N/A
- INKT N/A
- Revenue Next Year
- TURN N/A
- INKT N/A
- P/E Ratio
- TURN $17.34
- INKT N/A
- Revenue Growth
- TURN 277.43
- INKT N/A
- 52 Week Low
- TURN $3.12
- INKT $4.56
- 52 Week High
- TURN $5.01
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- TURN 86.44
- INKT 50.04
- Support Level
- TURN $7.73
- INKT $13.11
- Resistance Level
- TURN $8.74
- INKT $16.20
- Average True Range (ATR)
- TURN 0.25
- INKT 1.07
- MACD
- TURN 0.36
- INKT 0.02
- Stochastic Oscillator
- TURN 77.78
- INKT 55.63
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.